Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6852143 | 0.78 | CLK4 (0.30) | CLK4 | |
| Hydrochloric Acid SCHEMBL15911351 | 0.66 | PIK3CD (0.39) | CLK4CYP19A1 | |
| SCHEMBL6854012 | 0.66 | CLK4 (0.44) | CLK4 | |
| SCHEMBL6852128 | 0.66 | CYP19A1 (0.32) | CLK4CYP19A1 | |
| SCHEMBL6850807 | 0.64 | CYP2A6 (0.41) | CLK4CYP19A1 | |
| SCHEMBL6852359 | 0.63 | CYP19A1 (0.32) | CYP19A1 | |
| SCHEMBL6852349 | 0.63 | CYP19A1 (0.32) | CYP19A1 | |
| SCHEMBL6851724 | 0.61 | CYP19A1 (0.31) | CYP19A1 | |
| SCHEMBL6851728 | 0.61 | CYP19A1 (0.31) | CYP19A1 | |
| SCHEMBL13539329 | 0.61 | CYP2A6 (0.48) | CLK4CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1585775-A | 6-O-acyl ketolide derivatives of erythromycine useful as antibacterials | ORTHO MCNEIL PHARM INC (US) | 2005-02-23 | — | — | CN | disclosed |
| US-6825170-B2 | ERYTHROMYCIN TYPE MACROLIDE WITH A FUSED OXAZOLONE RING | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2004-11-30 | — | — | US | disclosed |
| EP-1453847-A1 | 6-O-ACYL KETOLIDE DERIVATIVES OF ERYTHROMYCINE USEFUL AS ANTIBACTERIALS | Ortho-Mcneil Pharmaceutical, Inc. (US) | 2004-09-08 | — | — | EP | disclosed |
| WO-2003050132-A1 | 6-O-ACYL KETOLIDE DERIVATIVES OF ERYTHROMYCINE USEFUL AS ANTIBACTERIALS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2003-06-19 | — | — | WO | disclosed |